Clozapine in drug-induced psychosis in Parkinson's disease

Lancet

Volumn 353, Issue 9169, 1999, Pages 2041-2042

  Pollak, P ^a   Destee, A ^a   Tison, F ^a   Pere, J J ^a   Bordiex, I ^a   Agid, Y ^a   Allain, H ^a   M Borg, ^a   Brousolle, E ^a   Durif, F ^a   Geny, C ^a   Prunier Levilon, C ^a   Rascol, O ^a   Sangla, S ^a   Verin, M ^a   Viallet, F ^a   Tranchant, C ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CLOZAPINE; LEVODOPA; NEUROLEPTIC AGENT; SELEGILINE;

AGRANULOCYTOSIS; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; COGNITION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SOMNOLENCE;

EID: 0033549287     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00860-0     Document Type: Article

References (5)

1. Baldessarini R.J., Frankenburg F.R. Drug therapy: clozapine - a novel antipsychotic agent. N Engl J Med. 324:1991;746-754.
2. Scholz E., Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci. 235:1985;60-64.
3. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 340:1999;757-763.
4. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiat. 155:1989;59-65.
5. Fahn S., Elton R.L., and Members for the UPDRS development committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information, 1987: 153-63.